PROCTER & GAMBLE HEALTH LIMITED
₹5,684.40+₹173.80 (+3.2%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹8,946 Cr
- P/E
- 29.2x
- Revenue
- ₹934 Cr
Price chart
Technical chartScreen technicals →-8.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +2.2%
- 3M
- -12.6%
- 6M
- +9.4%
- 1Y
- -8.0%
- 5Y
- +4.4%
52-week range
Day change +₹173.80 (+3.2%) from ₹5,511 to ₹5,684 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in PGHL, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Valuation attractive — PE of 29.2x is 70% below peer average of 98.6x
Concerns0
Rule-based from financial data. Not advice.
About the company
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands.
Read moreShow less
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble Health Limited is a subsidiary of Procter & Gamble Overseas India B.V.
- Sector
- Healthcare
- Shares outstanding
- 1.7 Cr shares
- ISIN
- INE199A01012
- BSE code
- 500126
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹8,946 Cr
- P/E
- 29.2x
- P/B
- 14.4x
- Earnings yield
- 3.4%
- 52-week high
- ₹6,914.45
- 52-week low
- ₹4,770.60
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹934 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -18.9%
Revenue and net profit
Annual revenue, with net profit as the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹1,009 Cr | ₹177 Cr |
| FY2022 | ₹1,114 Cr | ₹193 Cr |
| FY2023 | ₹1,230 Cr | ₹229 Cr |
| FY2024 | ₹1,151 Cr | ₹201 Cr |
Cash flows
FY2025: ₹169 Cr from operations, ₹179 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹247 Cr | ₹215 Cr |
| FY2022 | ₹170 Cr | ₹144 Cr |
| FY2023 | ₹236 Cr | ₹214 Cr |
| FY2024 | ₹228 Cr | ₹221 Cr |
| FY2025 | ₹169 Cr | ₹179 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Cash from operations
- ₹169 Cr
- Free cash flow
- ₹179 Cr-19.0%1Y
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | — | ₹169 Cr | ₹179 Cr | — | — | — |
Monthly returns
Month-by-month returns of PGHL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹794 Cr |
| Equity capital | ₹17 Cr |
| Reserves | ₹520 Cr |
| Borrowings | ₹8 Cr |
| Other liabilities | ₹250 Cr |
| Assets | ₹794 Cr |
| Fixed assets | ₹116 Cr |
| Capital work in progress | ₹11 Cr |
| Investments | ₹0 Cr |
| Other assets | ₹667 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
PGHL trades at 29.2x earnings against a peer median of 52.6x (a 44% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| PROCTER & GAMBLE HEALTH LIMITEDPGHLthis companyP/E ↓ discount | ₹8,946 Cr | 29.2x | 14.4x | — | — |
| JYOTHY LABS LIMITEDJYOTHYLAB | ₹9,555 Cr | 27.2x | 6.6x | 32.4% | 17.6x |
| HealthCare Global Enterprises LimitedHCG | ₹9,408 Cr | 513.0x | 8.0x | 2.8% | 49.9x |
| Sanofi India LtdSANOFI | ₹9,387 Cr | 25.4x | 12.0x | — | — |
| Jeena Sikho Lifecare LimitedJSLL | ₹8,968 Cr | 58.2x | 25.2x | 35.9% | 90.3x |
| Jupiter Life Line Hospitals LimitedJLHL | ₹8,877 Cr | 46.3x | 5.9x | 12.2% | 34.5x |
| Corona Remedies LimitedCORONA | ₹8,749 Cr | 55.1x | — | 18.8% | 55.0x |
| Blue Jet Healthcare LimitedBLUEJET | ₹8,659 Cr | 24.6x | 6.9x | 19.4% | 34.4x |
| STRIDES PHARMA SCIENCE LIMITEDSTAR | ₹8,552 Cr | 112.0x | 2.7x | 1.3% | 35.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
PGHL since 1 January, against earlier years.
Historical volatility
PGHL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
| Line | FYundefined |
|---|---|
| RevenueSales | — |
| Costs | |
| Interest | — |
| Expenses | — |
| Operating profitOperating Profit | — |
| Other income and charges | |
| Profit before tax | — |
| Tax | |
| Net profitNet Profit | — |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹794 Cr |
| Equity capitalEquity Capital | ₹17 Cr |
| Reserves | ₹520 Cr |
| Borrowings | ₹8 Cr |
| Other liabilitiesOther Liabilities | ₹250 Cr |
| AssetsTotal Assets | ₹794 Cr |
| Fixed assetsFixed Assets | ₹116 Cr |
| Capital work in progressCWIP | ₹11 Cr |
| Investments | ₹0 Cr |
| Other assetsOther Assets | ₹667 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹169 Cr |
| Investing cash flowCash from Investing Activity | ₹10 Cr |
| Financing cash flowCash from Financing Activity | -₹235 Cr |
| Change in cashNet Cash Flow | -₹56 Cr |
Learn while you research
Academy chapters picked for PROCTER & GAMBLE HEALTH LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read